Key result
Metformin and carbohydrate control improve acanthosis and induce menarche within 3 months in INSR mutation case.
Why the study?
Does metformin and carbohydrate control improve symptoms in an adolescent with a monogenic INSR mutation?
Case Report (n=1)
Does metformin and carbohydrate control improve symptoms in an adolescent with a monogenic INSR mutation?
Metformin and dietary modification can effectively manage symptoms of severe insulin resistance in patients with monogenic INSR mutations.
May support metformin consideration in rare INSR cases; leaves open generalizability pending controlled trials.
Insulin receptor mutations cause extreme insulin resistance resulting in acanthosis nigricans and hyperandrogenism. We report a pre-menarchal adolescent female with normal weight, with severe acanthosis nigricans, acne, and hirsutism. Initial investigation revealed elevated fasting and post-prandial insulin and high testosterone and androstenedione levels. Her father had frequent complaints of hypoglycemia. Coding sequence and splice junction analysis of the INSR gene, in our patient and her father, revealed a heterozygous missense mutation in the β subunit of the insulin receptor (Arg1131Trp), resulting in receptor loss of function. Metformin therapy and carbohydrate control improved acanthosis and menarche ensued within 3 months. Our case highlights the importance of distinguishing insulin resistance commonly associated with obesity from monogenic defects. Although, there is no consensus on treatment of children with monogenic forms of insulin resistance due to its rarity, dietary and lifestyle modifications and insulin-sensitizing agents play a key role in management.
No takes yet. Share an insight, caveat, or question.
Krishnamurthy et al. (2016) conducted a case report in Acanthosis nigricans and hyperandrogenism (n=1). Metformin therapy and carbohydrate control was evaluated on Improvement of acanthosis and onset of menarche. Metformin therapy and carbohydrate control improved acanthosis and induced menarche within 3 months in an adolescent with a novel INSR gene mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: